184 related articles for article (PubMed ID: 126436)
1. [Clinical conference: Histaaminemia in myeloproliferative syndromes].
Cadiou M; Ruff F; Meunier F; Attalah N; Bernadou A; Zittoun R; Parrot JL; Bousser J
Nouv Rev Fr Hematol; 1975; 15(2):261-9. PubMed ID: 126436
[No Abstract] [Full Text] [Related]
2. [Metamorphosis of chronic myeloproliferative diseases].
Butoianu E; Nicoară S; Coliţă A; Ursea C; Berceanu S
Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Med Interna; 1983; 35(3):223-32. PubMed ID: 6140716
[No Abstract] [Full Text] [Related]
3. [Association of hemorrhagic and thrombotic phenomena in myeloproliferative syndromes].
Meschengieser SS; Woods AI; Schattner MA; Lazzari MA
Medicina (B Aires); 1981; 41 Suppl():267-73. PubMed ID: 6954340
[No Abstract] [Full Text] [Related]
4. Studies on the phagocytic activity of neutrophilic leukocytes.
Brandt L
Scand J Haematol Suppl; 1967; 2():1-126. PubMed ID: 5243720
[No Abstract] [Full Text] [Related]
5. [Radioimmunometric determination of histamine in myeloproliferative syndromes].
Bettelheim P; Valent P
Wien Klin Wochenschr; 1989 Oct; 101(20):706-10. PubMed ID: 2480027
[TBL] [Abstract][Full Text] [Related]
6. Platelets in the myeloproliferative syndrome.
Weinfeld A; Branehög I; Kutti J
Clin Haematol; 1975 Jun; 4(2):373-92. PubMed ID: 1102193
[No Abstract] [Full Text] [Related]
7. Blood histamine in the differential diagnosis of myeloid splenomegaly (osteomyelofibrosis) and other myeloproliferative disorders.
Gingold N
Rev Roum Med; 1974; 12(1):15-8. PubMed ID: 4533361
[No Abstract] [Full Text] [Related]
8. Thrombohaemorrhagic complications in 101 cases of myeloproliferative disorders: relationship to platelet number and function.
Barbui T; Cortelazzo S; Viero P; Bassan R; Dini E; Semeraro N
Eur J Cancer Clin Oncol; 1983 Nov; 19(11):1593-9. PubMed ID: 6580171
[TBL] [Abstract][Full Text] [Related]
9. [Familial myeloproliferative syndromes. Study of 6 families and review of literature].
Kaufman S; Brière J; Bernard J
Nouv Rev Fr Hematol (1978); 1978 Apr; 20(1):1-15. PubMed ID: 353725
[TBL] [Abstract][Full Text] [Related]
10. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
[TBL] [Abstract][Full Text] [Related]
11. [Comprehensive care of patients with thrombocythemia].
Hrubisková K; Steruská M; Horváth A
Vnitr Lek; 1987 Oct; 33(10):872-82. PubMed ID: 3479860
[No Abstract] [Full Text] [Related]
12. The role of beta-catenin in chronic myeloproliferative disorders.
Jauregui MP; Sanchez SR; Ewton AA; Rice L; Perkins SL; Dunphy CH; Chang CC
Hum Pathol; 2008 Oct; 39(10):1454-8. PubMed ID: 18619646
[TBL] [Abstract][Full Text] [Related]
13. Pathogenetic mechanisms in chronic myeloproliferative disorders: polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, and chronic myelogenous leukemia.
Tefferi A
Semin Hematol; 1999 Jan; 36(1 Suppl 2):3-8. PubMed ID: 9930550
[TBL] [Abstract][Full Text] [Related]
14. [Granulocyte clearance and granulocyte kinetics in myeloproliferative syndromes].
Jungi WF; Meuret G; Senn HJ
Schweiz Med Wochenschr; 1974 Jan; 104(4):133-5. PubMed ID: 4521299
[No Abstract] [Full Text] [Related]
15. Diagnosis and management of myeloproliferative disorders.
Laszlo J; Huang AT
Curr Probl Cancer; 1977 Jul; 2(1):1-42. PubMed ID: 268266
[No Abstract] [Full Text] [Related]
16. [MYELOPROLIFERATIVE SYNDROMES].
PIRESWDA F
Folha Med; 1964 Apr; 48():195-201. PubMed ID: 14271209
[No Abstract] [Full Text] [Related]
17. In vitro culture techniques defining biological abnormalities in the myelodysplastic syndromes and myeloproliferative disorders.
Greenberg PL
Clin Haematol; 1986 Nov; 15(4):973-93. PubMed ID: 3552351
[No Abstract] [Full Text] [Related]
18. Quantitative and functional studies of impaired natural killer (NK) cells in patients with myelofibrosis, essential thrombocythemia, and polycythemia vera. I. A potential role for platelet-derived growth factor in defective NK cytotoxicity.
Gersuk GM; Carmel R; Pattamakom S; Challita PM; Rabinowitz AP; Pattengale PK
Nat Immun; 1993; 12(3):136-51. PubMed ID: 8329837
[TBL] [Abstract][Full Text] [Related]
19. [Clinical aspects of myeloproliferative disorders excluding CML].
Komatsu N
Rinsho Ketsueki; 2008 Oct; 49(10):1411-9. PubMed ID: 18833926
[No Abstract] [Full Text] [Related]
20. [The treatment of myeloproliferative syndromes].
Maurice P
Schweiz Med Wochenschr; 1975 Oct; 105(40):1269-74. PubMed ID: 1061995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]